Vericel Prices $65MM Public Offering of Stock

Vericel (VCEL), developer of MACI autologous cultured chondrocyte product for cartilage repair, priced its underwritten public offering of 5MM shares of common stock at $13/share. The offering is slated to close by June 5.

Gross proceeds are expected to be $65MM before deducting expenses. The company granted underwriters 30 days to purchase up...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0